Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study Research Letter

  

Authors:	Hamlin, P. A.; Flinn, I. W.; Wagner-Johnston, N.; Burger, J. A.; Coffey, G. P.; Conley, P. B.; Michelson, G.; Leeds, J. M.; Der, K.; Kim, Y.; Sabalvaro-Torres, A.; Birrell, M.; Pandey, A.; Curnutte, J. T.; Patel, M. R.
Title:	Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
Journal Title:	American Journal of Hematology
Volume:	94
Issue:	4
ISSN:	0361-8609
Publisher:	John Wiley & Sons, Inc.
Date Published:	2019-04-01
Start Page:	E90
End Page:	E93
Language:	English
DOI:	10.1002/ajh.25387
PUBMED:	30592080
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059672928&doi=10.1002%2fajh.25387&partnerID=40&md5=af9eeb4ea9efd0a4ed6a206b9f114b0f
Notes:	Letter -- Export Date: 1 April 2019 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/144606